NanoViricides, Inc. Anti-Herpes Drug Candidate Reduces Viral Load by 99.99%
NanoViricides (NNVC Charts) jumped 29% today on this great news.
click chart courtesy of stockcharts.com for full size image
Press Release
Source: NanoViricides, Inc.
On Monday August 10, 2009, 7:00 am EDT
WEST HAVEN, Conn.--(BUSINESS WIRE)-- NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that the herpes simplex viral load was reduced by 99.99% or 10,000 fold in in-vitro studies by nanoviricides(TM) drug candidates. The studies were performed by Thevac in Baton Rouge, LA, in collaboration with the Division of Biotechnology and Molecular Medicine at the LSU School of Veterinary Medicine under the supervision of Dr. Gus Kousoulas.
Four different nanoviricides showed greater than 10,000-fold (>99.99%) reduction in virus quantity compared to untreated controls in a cell culture assay employing the LSU proprietary green-fluorescent-protein-tagged (GFP) modified HSV-1 McKrae strain.
These nanoviricide drug candidates are designed to act against all herpes simplex virus strains, including HSV-1 and HSV-2. The Company has commissioned additional in vitro studies to confirm the results. Animal studies have also been scheduled.
"We are very excited with this success against HSV-1," said Eugene Seymour, MD, MPH, CEO of the Company, adding "and expect this to lead to a topical skin cream against herpes cold sores and genital herpes. This opens up another significant commercial opportunity for the Company."
Herpes simplex virus (HSV) causes "cold sores", the incidence of which is second only to the common cold (100 million recurrences annually in the US alone). In addition, genital herpes prevalence is 67 million infected individuals in the US alone. HSV also causes keratitis, a disease of the eye (250,000 US cases/year).
Existing therapies include acyclovir and drugs chemically related to it. These drugs, nucleoside analogs, act by inhibiting viral DNA synthesis. However, there is known drug toxicity due to interference with human metabolism. Currently, there is no cure for herpes infection.
Nanoviricides act by a novel and distinctly different mechanism compared to existing drugs. Nanoviricides are designed to mimic the human cell surface to which the virus binds. Our results suggest that a nanoviricide could become a highly sought after drug against HSV.
The market size for herpes simplex virus treatments is in excess of $2 billion annually.
This press release contains forward-looking statements .... more here
NanoViricides (NNVC Charts) jumped 29% today on this great news.
click chart courtesy of stockcharts.com for full size imagePress Release
Source: NanoViricides, Inc.
On Monday August 10, 2009, 7:00 am EDT
WEST HAVEN, Conn.--(BUSINESS WIRE)-- NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that the herpes simplex viral load was reduced by 99.99% or 10,000 fold in in-vitro studies by nanoviricides(TM) drug candidates. The studies were performed by Thevac in Baton Rouge, LA, in collaboration with the Division of Biotechnology and Molecular Medicine at the LSU School of Veterinary Medicine under the supervision of Dr. Gus Kousoulas.
Four different nanoviricides showed greater than 10,000-fold (>99.99%) reduction in virus quantity compared to untreated controls in a cell culture assay employing the LSU proprietary green-fluorescent-protein-tagged (GFP) modified HSV-1 McKrae strain.
These nanoviricide drug candidates are designed to act against all herpes simplex virus strains, including HSV-1 and HSV-2. The Company has commissioned additional in vitro studies to confirm the results. Animal studies have also been scheduled.
"We are very excited with this success against HSV-1," said Eugene Seymour, MD, MPH, CEO of the Company, adding "and expect this to lead to a topical skin cream against herpes cold sores and genital herpes. This opens up another significant commercial opportunity for the Company."
Herpes simplex virus (HSV) causes "cold sores", the incidence of which is second only to the common cold (100 million recurrences annually in the US alone). In addition, genital herpes prevalence is 67 million infected individuals in the US alone. HSV also causes keratitis, a disease of the eye (250,000 US cases/year).
Existing therapies include acyclovir and drugs chemically related to it. These drugs, nucleoside analogs, act by inhibiting viral DNA synthesis. However, there is known drug toxicity due to interference with human metabolism. Currently, there is no cure for herpes infection.
Nanoviricides act by a novel and distinctly different mechanism compared to existing drugs. Nanoviricides are designed to mimic the human cell surface to which the virus binds. Our results suggest that a nanoviricide could become a highly sought after drug against HSV.
The market size for herpes simplex virus treatments is in excess of $2 billion annually.
This press release contains forward-looking statements .... more here
 |  |
 |
At $0.99 the market cap for NNVC is only $121.79M
For commentary and my current outlook for NNVC, read "Kirk's Investment Newsletter"
Disclaimer: I own NNVC in my personal and newsletter accounts with shares added at 56¢ and 80¢ for overall profits in my position as of this writing. I have targets to take profits on these shares listed in the newsletter should my price objective be reached. I will not announce buying or selling ahead of time here on the blog.
Disclaimer: I own NNVC in my personal and newsletter accounts with shares added at 56¢ and 80¢ for overall profits in my position as of this writing. I have targets to take profits on these shares listed in the newsletter should my price objective be reached. I will not announce buying or selling ahead of time here on the blog.
- NNVC Charts
- FREE Sample Issue of "Kirk Lindstrom's Investment Letter"
| Date | Open | High | Low | Close | Volume |
| 10-Aug-09 | 0.81 | 1.09 | 0.79 | 0.99 | 1,332,103 |
| 7-Aug-09 | 0.75 | 0.77 | 0.72 | 0.77 | 125,700 |
| 6-Aug-09 | 0.76 | 0.76 | 0.71 | 0.75 | 106,300 |
| 5-Aug-09 | 0.73 | 0.75 | 0.71 | 0.73 | 36,100 |
| 4-Aug-09 | 0.75 | 0.77 | 0.72 | 0.75 | 64,700 |
| 3-Aug-09 | 0.73 | 0.77 | 0.71 | 0.77 | 94,700 |
| 31-Jul-09 | 0.76 | 0.78 | 0.71 | 0.76 | 219,900 |
| 30-Jul-09 | 0.71 | 0.78 | 0.71 | 0.75 | 120,400 |
Posts
kirklindstrom.com
August 12, 2009 07:00 AM Eastern Daylight Time
ReplyDeleteNanoViricides, Inc. Herpes Study Results Discussed on CBS News Report
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reported today that the CBS affiliate TV station WBRZ interviewed Professor K. Gus Kousoulas , PhD, in which he explained the potential implications of the Company’s nanoviricides™ anti-Herpes drug candidates.
“Over 90% of the people are infected with Herpes, whether they know it or not,” said Dr. Kousoulas, adding “it can manifest as cold sores or genital herpes. [These manifestations] can be very painful, especially for women.” He also commented that “Unlike true love, herpes is forever,” referring to the fact that the herpes virus goes dormant in the body between recurrent manifestations, and that there is at present no cure for herpes.
“A nanoviricide drug could be an important breakthrough,” he said, explaining, “the duration of a cold sore could be reduced drastically, from a month to just a few days [by applying a nanoviricide skin cream],” based on studies conducted in the laboratories at the Louisiana State University’s (LSU) Division of Biotechnology and Molecular Medicine (BIOMMED). In cell culture testing, his laboratory found that certain nanoviricides eliminated 99.99% of the virus from infected cells.
A video excerpt of the interview can be found at 2theadvocate.com | News | Possible progress in herpes treatment — Baton Rouge, LA. The video was also linked to the front page of The Drudge Report, DRUDGE REPORT 2009®.
The LSU School of Veterinary Medicine has received a grant of $11.1M in July 2009, adding to a previous award of $9.9M in 2004, for the LSU Center of Biomedical Research Excellence (COBRE) from the National Institutes of Health (NIH). Konstantin G. Kousoulas, PhD, Professor of Veterinary Virology and Director of BIOMMED, is the administrator of the COBRE program at the LSU School of Veterinary Medicine. He is also the Mary Louise Martin Professor of Virology and the Director of LSU-Tulane Center for Experimental Infectious Disease Research.
Hi,
ReplyDelete1 in 4 sexually active teenagers become infected with an STD every year, in the United States alone. Now, more than ever, we need to join together to fight this growing issue. As I read through your website, it is clear that you share the same passion for STD/STI awareness. We here, at Disease.com, understand the importance of STD/STI prevention and treatments. If you could, please list us as a resource or host our social book mark button, it would be much appreciated. We can not reach every teenager, but together we can try.
If you need more information please email me with the sublect line as your URL.
Thank you,
Sharon Vegoe
Disease.com
please help with a cure its so annoying. i want a normal love life and sex life.
ReplyDelete